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The immune system has a key role to play in controlling cancer initiation and progression.
T cell activation, which is central to anti-tumor immune responses, coincides with changes
in cellular metabolism. Naïve T cells predominantly require an ATP generating metabolic
profile, whereas proliferating effector T cells require anabolic metabolic profiles that pro-
mote rapid growth and proliferation. Furthermore, specific T cell subsets require distinct
energetic and biosynthetic pathways to match their functional requirements. The often
hostile tumor microenvironment can affectT cell immune responses by altering the result-
ing cellular metabolism. Tailoring immune responses by manipulating cellular metabolic
pathways may provide an exciting new option for cancer immunotherapy.T cell responses
might also be skewed via metabolic manipulation to treat the complications of obesity-
associated inflammation, which is a rapidly growing global health problem and a major
risk factor for many malignancies. In this review, the diverse metabolic requirements of
T cells in anti-tumor immunity are discussed, as well as the profound influence of the
tumor microenvironment and the possible avenues for manipulation to enhance anti-tumor
immunity.
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INTRODUCTION
A unique bioenergetic challenge is faced by cells of the immune
system when they recognize mutated or over expressed tumor
antigens presented by antigen presenting cells. They must rapidly
proliferate with a specific phenotype and function to eradicate
tumor cells (1). The ability of a T cell to transition from a naïve,
to effector, to a memory phenotype is determined by metabo-
lism and the metabolic program varies to match the T cell subset
in order to enable cell survival and function (2). Activated T
cells switch from naïve T cells, mainly requiring generation of
ATP and replacement biosynthesis (3) to effector T cells (TEFF),
which must rapidly increase cell mass and elicit effector functions
through cytokine production and cytotoxicity (4). This switch
from primarily oxidative phosphorylation (OxPhos) to glycoly-
sis supports the demands of rapid cell growth. Primary fuels and
amino acids, such as glucose and glutamine must be available
to support these distinct metabolic pathways (5, 6). Unavailabil-
ity of these fuels occurs during malnutrition and can lead to
immunosuppression (7), while excess fuel in diet-induced obe-
sity is associated with a constant low level state of inflammation
(8). We have previously identified T cells as key players in adi-
pose tissue inflammation in obesity-associated cancer and here,
we suggest that their metabolism might be targeted to control
chronic inflammation and lessen the clinical manifestations of
obesity (9). In comparison, the long lifespan of memory T cells
(TMEM) poses a different metabolic demand and to facilitate this
need, TMEM cells utilize fatty acid oxidation (FAO) as their main
energy source (10). The balance between different T cell subsets
can be altered by multiple environmental factors in the tumor
resulting in the activation of metabolic pathways and the estab-
lishment of inappropriate T cell responses. Direct manipulation
of T cell metabolism has the potential to provide a new avenue for
cancer immunotherapy and obesity-associated inflammation and
this will be discussed.
HOW T CELL METABOLISM AFFECTS FUNCTION
At each stage of a T cell’s development, its metabolism must sup-
port the function of the cell through the provision of energy and
biosynthetic precursors (11) (Figure 1). It is vital that T cells
undergo the appropriate activation and differentiation to ensure
that homeostasis is maintained (12).
NAÏVE T CELLS
The primary function of naïve T cells is antigenic surveil-
lance, which requires relatively small amounts of ATP to sup-
port processes such as ion homeostasis, membrane integrity, and
rearrangement of the actin cytoskeleton for movement (13). Thus
naïve T cells have a catabolic metabolic profile that favors energy
production over biosynthesis (14). It is estimated that 96% of ATP
in naïve T cells is generated through OxPhos, with the remaining
4% being generated by glycolysis (3). It is an oxygen dependent
process and produces 36 molecules of ATP per glucose mole-
cule (1). Naïve T cells require extrinsic signals to maintain this
basal metabolism. Interleukin-7 (IL-7) regulates glucose uptake
via the cell surface trafficking of Glut1, which is modulated by the
PI3K/Akt/mTOR pathway (15). This regulation of glucose uptake
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FIGURE 1 | Changes inT cell metabolism are related to function: Over the
course of an immune response the metabolism of aT cell changes. Naïve
T cells mainly used a mixed fuel OxPhos to produce ATP. Once activated the T
cell adopts a metabolic profile that is similar to many cancer cells (Warburg
effect). Consumption of glucose and glutamine increases to support
increased cell growth and proliferation. A subset of activated T cells survives
to become TMEM reverting back to lipid oxidation with increased capacity for
efficient energy generation and survival. Activation of T cells results in
changes in migration patterns to ensure they can successfully migrate to
areas of inflammation and cancer.
by IL-7 is critical to maintain homeostasis and to prevent apoptosis
by the pro-apoptotic protein Bim (16).
ACTIVATED T CELLS
In contrast, TEFF cells adopt an anabolic metabolic profile to meet
the increased energy requirements associated with cell growth,
proliferation, differentiation, and effector functions (4). TEFF cells
utilize aerobic glycolysis even though it is less efficient than OxPhos
yielding only four moles of ATP per glucose molecule (17). Aero-
bic glycolysis provides advantages over OxPhos in rapidly dividing
cells; firstly, metabolic intermediates needed for cell growth and
proliferation are generated by aerobic glycolysis (11). Secondly,
increased OxPhos results in increased production of reactive oxy-
gen species (ROS), which can lead to apoptosis of T cells (18).
Thirdly, aerobic glycolysis produces ATP faster than OxPhos.
Therefore, once glucose is not a limiting factor, the pace of gly-
colytic flux will produce enough ATP to meet the energy demand
of the TEFF cells (19). Finally glycolysis is not oxygen dependent
and can accommodate T cell survival in a hypoxic environment, a
common feature of many solid malignancies (20). OxPhos is still
utilized in TEFF cells however aerobic glycolysis is the main path-
way for glucose metabolism (21). Activated T cells must engage
distinct transcriptional programs to both establish their differen-
tiation status and elicit the effector functions required (22). These
changes are similar to those observed in rapidly dividing tumor
cells with many of the same metabolic regulators involved, includ-
ing mTOR (23). The main transcription factors up-regulated by
mTOR are c-Myc and hypoxia-inducible factor-1α (HIF-1α) and
it appears that only c-Myc is necessary for the glycolytic switch
that occurs during early T cell growth and proliferation. mTOR
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dependent up-regulation of c-Myc in the first 24 h following T
cell activation is crucial in the transition from a naïve T cell to a
TEFF cell (21). Effector CD4+ T cells can be distinguished from
effector CD8+ T cells due to their ability to increase OxPhos by
up to two-fold after activation, whereas activated CD8+ T cells do
not increase OxPhos above that of resting cells (24). This results in
activated CD4+ T cells having a survival advantage over CD8+ T
cells when pro-glycolytic signals are limited (25). CD8+ T cells exe-
cute the majority of immune-mediated tumor killing through the
release of cytolytic factors, such as perforin and granzymes (26).
Depending on the polarizing signals in the tumor microenviron-
ment the different CD4+ T cell subsets can promote or suppress
a defensive host response to cancer (27). Each CD4+ T cell subset
has a unique metabolic profile, which is adapted to its function
with Th1, Th2, and Th17 cells displaying a glycolytic metabolic
phenotype (28). In contrast to Th1 and Th17 cells, Th2 cells
readily develop in the absence of mTORC1 but fail to develop
in the absence of mTORC2 (29). TREG cells unlike other TEFF cells
mainly use lipid metabolism and have elevated levels of AMPK
activation (28). The utilization of lipid oxidation by TREG cells
might play a central role in their survival advantage over TEFF cells
and in the maintenance of a stable pool of pro-tumor immune
cells (30).
One area that currently warrants further investigation is how
metabolism affects, and is affected by migration of activated T cells.
Migration from nutrient and oxygen rich regions of the periph-
eral blood and lymphatics to the often hypoxic and acidic tumor
microenvironment can have a major impact on T cell metabolism
and their resulting effector function (31). Naïve and TMEM cells
circulate continuously among the blood vessels, lymph vessels, and
lymphatic tissue, whereas activated T cells must suspend migration
in the lymphoid tissue to proliferate and then regain their motility
to migrate to the tumor (32). Naïve and TMEM cells express CD62L,
CCR7, and sphingosine-1-phosphate (S1P), which allows homing
to and retention in secondary lymphoid organs (33) (Figure 1).
Activation of the PI3K-Akt-mTOR pathway down regulates
CD62L, CCR7, and S1P (34). Activation of this pathway also leads
to up-regulated expression of pro-inflammatory adhesion mole-
cules such as very late antigen-4 (VLA-4) and chemokine receptors
such as CXCR3 (32). These changes allow TEFF cells to migrate to
areas of inflammation and might influence their prevalence in
visceral adipose tissue (VAT), where they play a pathological role
in driving obesity-associated inflammation (9, 33).
MEMORY T CELLS
Following resolution of an immune response most TEFF cells
undergo apoptosis while some remain as TMEM cells, responsi-
ble for enhanced immunity against future re-exposure to invading
pathogens or tumors (35). While TEFF cells proliferate rapidly
and are short-lived, TMEM cells have lower turnover rates. This
long life span of TMEM cells poses a unique metabolic demand
on these cells. The production of a stable pool of TMEM cells
is reliant on a corresponding decrease in mTOR signaling and
a shift to fatty acid oxidation (FAO) (36). TMEM cells unlike
naïve and TEFF cells have a greater spare respiratory capac-
ity (SRC) in their mitochondria (37) (Figure 1). This allows
for rapid ATP production, which gives a bioenergetic advantage
upon secondary exposure to its antigen (38). IL-15 increases SRC
by enhancing mitochondrial biogenesis and the expression of
carnitine palmitoyltransferase I (CPTI). CPTI is a key enzyme
involved in FAO. Since FAO takes place in the mitochondria,
TMEM cells can increase their use of fatty acids for energy via
OxPhos, with a consequential decrease in dependence on glycol-
ysis. This results in TMEM cells having a survival advantage over
TEFF cells in the absence of pro-glycolysis signals, when the initial
priming antigen has been eliminated and cytokines such as IL-2
dissipate (37).
HOW THE TUMOR MICROENVIRONMENT CAN AFFECT T
CELL METABOLISM
HYPOXIA
Tumor growth tends to outgrow the developing blood supply
resulting in a hypoxic microenvironment (39). This hypoxic envi-
ronment can have multiple effects on T cell responses. Roman
et al. demonstrated that under hypoxic conditions the secretion
of effector CD4+ cytokines such as IFN-α was increased result-
ing in an increased immune response (40). In contrast, other
studies have found that hypoxia results in an impaired immune
response as a result of reduced IL-2 (41). Hypoxia can affect T
cell metabolism through the increased production of lactate by
tumor cells within the tumor microenvironment. An increase
in lactate in the tumor microenvironment results in decreased
T cell proliferation and cytokine production, due to decreased
glycolysis (42). HIF-1α is a master transcriptional regulator in
the response to low O2 levels and is also involved in neoplas-
tic pathways, including angiogenesis, cell survival, and treatment
resistance (43). Levels of HIF-1α increase in activated T cells
and can also be induced by other stimuli under normoxic con-
ditions such as mTOR signaling (44, 45). HIF-1α is responsible
for the glycolytic response that occurs downstream of mTORc1
activation (46). With the exception of Th17 cells, the role of
HIF-1α in T cell subset differentiation within the tumor microen-
vironment has not been clearly defined in the literature and
focused studies examining the role of HIF-1α on specific T cell
subsets are warranted. Some studies examining T cells in gen-
eral have shown that it can decrease activated T cell numbers
through increased apoptosis (47). Other studies have demon-
strated opposing results, showing that HIF-1α prevents apoptosis
by up-regulating adrenomedullin (48). A few studies have shown
that HIF-1α plays an important role in the differentiation of
Th17 cells, which are highly glycolytic and are believed to rely
more on glycolysis than other T cell subsets (49). Induction of
both Th17 and TREG responses are closely related as they share
a common requirement for transforming growth factor (TGF)-β.
The expression of HIF-1α plays an important role in regulating
the balance of Th17/TREG responses as it inhibits differentiation
of TREG cells by targeting Foxp3 for proteasomal degradation
(50). It also directly regulates Th17 differentiation by activating
transcription of RORγt and collaborates with RORγt to activate
Th17 signature genes, such as the IL-17 gene during development
(50). The up-regulation of HIF-1α results in high levels of gly-
colysis in Th17 cells by increasing the expression of Glut1 and
enzymes such as pyruvate kinase muscle (PKM) (49). Together
with the downregulation of mitochondrial oxygen consumption,
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this prevents the entry of pyruvate into the TCA cycle (51). It
is therefore likely that the constant state of low level inflamma-
tion present in many tumors may be due, at least in part, to
HIF-1α directed Th17 cell differentiation and decreased TREG cell
differentiation (50). A Th17 driven immune response has been
linked to infection induced colon cancer in mouse models (52)
and Helicobacter Pylori infection which can induce gastric can-
cer (53). Research has recently discovered that not all Th17 cells
are pathogenic and drive autoimmune tissue injury (54). Devel-
opment of pathogenic Th17 cells is dependent on exposure to
IL 23, which diminishes the production of the anti-inflammatory
cytokine IL-10 (55).
NUTRIENT DEPRIVATION
Reduction of nutrients present in the microenvironment is associ-
ated with an impaired anti-tumor immune response (56). Nutri-
ent deprivation inhibits mTOR activity which is vital for T cell
metabolism (57). Glucose is essential for TEFF cell survival and
proliferation (5), IFN-γ production (58), and cytolytic activity via
production of granzyme and perforin (59). T cell proliferation
is inhibited in the absence of glucose even when other meta-
bolic substrates such as fatty acids and glutamine are present
(58). T cell activation is also dependent on extracellular gluta-
mine (6). Glutamine is converted to glutamate and subsequently
to α-ketoglutarate, which enters into the TCA cycle to generate
citrate and pyruvate. This process is known as anaplerosis. It
replaces the metabolites that are removed from the TCA cycle for
the biosynthesis of fatty acids, nucleotides, and proteins allowing
the TEFF cells to maintain the integrity of the TCA cycle function
(60). Chang et al. demonstrated that lymphoma cells can impose
nutrient deprivation on T cells by depleting glucose and gluta-
mine resources. This can lead to decreased release of cytokines,
such as IFN-γ, from TEFF cells (61). Arginine is an example of
another amino acid which is vital for many T cell functions such
as proliferation (62). Research carried out by Rodriguez et al.
demonstrated that myeloid derived suppressor cells in the tumor
microenvironment express high levels of arginase-1. The result-
ing lower levels of arginine led to inhibition of T cell receptor
expression and antigen specific T cell responses (63). Sequestra-
tion of cysteine by myeloid derived suppressor cells is another
way in which amino acid deprivation occurs and subsequently
results in the inhibition of T cell activation (64). Tumor cells
and non-malignant stromal cells can elicit immunosuppressive
effects through the expression of amino acid catabolic enzymes,
such as indoleamine 2,3-dioxygenase (IDO) which catalyzes the
degradation of tryptophan (65). In fact, IDO expression by tumor
cells has been shown to correlate with a poor clinical prognosis
in several cancers including ovarian (66) and endometrial cancer
(67). Elevated IDO expression causes both the depletion of tryp-
tophan and the production of immunosuppressive tryptophan
metabolites (68). Such metabolites can impair T cell function (69)
and lead to T cell apoptosis (70), thus resulting in less effective
anti-tumor T cell responses. Nutrient limitation can also induce
autophagy in TEFF cells, as a survival mechanism to generate an
intracellular source of nutrients (71). Reduced levels of amino acid
or decreased ATP/AMP ratios result in AMPK activation, which
phosphorylates the protein kinase unc-51-like kinase 1/2 (Ulk1/2).
Activation of Ulk1/2 then initiates autophagy (72). In addition to
autophagy, increased metabolic stress due to nutrient deprivation
can ultimately lead to T cell apoptosis (73).
CHRONIC T CELL ACTIVATION
Chronic T cell activation occurs due to constant antigen expo-
sure and can induce a state of T cell non-responsiveness termed
exhaustion. T cell exhaustion is defined by poor effector function,
continued expression of inhibitory receptors, and a gene expres-
sion profile distinct from TEFF or TMEM cells (74). The tumor
microenvironment establishes an immunosuppressive environ-
ment in which T cells respond in a similar manner to exhausted T
cells in chronic viral infections (75). This may partially explain
why tumors continue to grow despite the presence of tumor
specific T cells (76). Baitsch et al. examined T cells from metas-
tases in patients with advanced stage III–IV melanoma and
found that these T cells exhibited an exhaustion profile and
produced insufficient levels of IFN-γ. The T cell exhaustion
at the metastatic tumor sites was induced by continuous anti-
gen exposure coupled with inhibitory signals from tumor cells
and non-malignant stromal cells (77). The programed death
receptor 1 (PD-1) is an immune-inhibitory receptor, which is
expressed on chronically activated T cells. Ahmadzadeh et al.
found increased expression of this receptor on tumor infiltrat-
ing T cells compared with T cells in peripheral tissue and the
blood of patients with metastatic melanoma. The augmented PD-
1 expression was associated with impaired effector function in
these T cells, decreased proliferation, and reduced ability to differ-
entiate into TMEM cells (76). Cytotoxic T-lymphocyte antigen-4
(CTLA-4) is another negative regulator of T cells, which is up-
regulated following T cell activation and during T cell exhaustion
(78). Higher levels of CTLA-4 expression on T cells out com-
petes CD28 for binding to CD80 and CD86 on the antigen pre-
senting cell, thus preventing co-stimulation of the T cell (79).
CTLA-4 and PD-1 also participate in the regulation of cellular
metabolism by blocking CD28-mediated metabolic changes fol-
lowing T cell activation. Ligations of CTLA-4 and PD-1 have
been shown to inhibit PI3K/Akt/mTOR signaling resulting in
diminished glucose uptake and glycolytic rate (80). Binding of
CTLA-4 expressed on TREG cells to CD80 and CD86 on den-
dritic cells is believed to suppress T cell responses through the
up-regulation of IDO expression, thus revealing another mech-
anism through which CTLA-4 can contribute to tumor antigen
tolerance.
TARGETING T CELL METABOLISM; A NEW AVENUE FOR
CANCER IMMUNOTHERAPY
Dysregulation of T cell subsets can result in many immune-
mediated disorders, due to a disruption in the balance between
protective immunity and suppression of pathological inflam-
mation (1). Modulation of immune cell metabolism has been
investigated in conditions where there is a chronic overreac-
tion of the immune system, such as asthma. Chronically acti-
vated CD4+ T cells isolated from asthma patients have been
shown to overexpress pyruvate dehydrogenase kinase-1 (PDK-
1), which results in the production of high levels of lactate
which promotes aerobic glycolysis. Treatment with the PDK-1
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inhibitor dichloroacetate (DCA) inhibited the proliferation of T
cells and reduced inflammatory cytokine production by switching
the metabolism back to OxPhos. In mouse models this resulted in
reduced airway inflammation (81). This study, together with oth-
ers, has attempted to dampen excessive inflammatory responses
through attenuation of TEFF cell responses and enhancement
of TREG cell responses by targeting metabolic pathways. Treat-
ment of T cells isolated from a mouse model of asthma with
metformin induced the generation of TREG cells through the
activation of AMPK and therefore, conferred protective immu-
nity without inappropriate inflammation (28). Metformin is an
oral anti-diabetic drug, which reduces hepatic glucose production
and increases insulin sensitivity and glucose uptake by muscles
and adipocytes, resulting in decreased insulinemia and insulin
sensitivity (82). Zhou et al. demonstrated that following inhibi-
tion of complex I of the mitochondrial respiratory chain, met-
formin induces a decrease in ATP synthesis and increases the
AMP/ATP ratio, thus stimulating AMPK (83). Studies targeting
T cell metabolism have already been conducted in mouse mod-
els of arthritis, lupus, uveitis, and asthma and similar studies in
obesity-associated cancer might elucidate a mechanism by which
the T cell inflammatory responses can be abrogated in adipose
tissue to attenuate tumor-promoting chronic inflammation (84–
87). Targeting T cell metabolism for cancer immunotherapy must
take a different approach by augmenting the beneficial anti-tumor
responses of TEFF cells initially, leading to TMEM cell genera-
tion and by attenuating the responses of TREG cells. A detailed
understanding of the exact metabolic needs of different T cell
subsets will allow therapies to be designed in order to achieve
this (27).
DECREASING TREG CELL PROLIFERATION
Increased numbers of TREG cells within the tumor microenviron-
ment have been reported in patients with cancer (88) and are
associated with a poorer outcome (89). One theory proposed is
that tumor cells both secrete and induce the secretion of TGF-β/IL-
10 from immature dendritic cells and results in the generation
of TREG cells from CD4+CD25− naïve T cells (90). It has been
demonstrated in mouse models of cancer that depletion of TREG
cells improves endogenous immune-mediated tumor rejection
(91). Clinical trials have shown the feasibility and relative safety of
managing TREG cells in human cancer, although treatment effects
have been modest. Ontak is a monovalent human IL-2 fusion toxin
licensed to treat human CD25+ cutaneous T cell lymphoma (92).
Due to the phenotypic similarity of CD4+CD25+ cutaneous T cell
lymphoma cells and CD4+CD25+ TREG cells, Ontak was tested
in many cancers. Some studies demonstrated depletion in TREG
cell numbers and improved immunity in patients with metastatic
ovarian carcinoma (93), while other studies showed no benefit in
melanoma patients (94). Modulation of TREG cell metabolism to
suppress their differentiation is a novel approach being investi-
gated in vivo. TREG cells require lipid oxidation for differentiation
and treatment of these cells with etomoxir, a CPT1A blocker, has
been successful in suppressing TREG cell generation (Figure 2).
This study is very promising for cancer therapy due to the fact that
TREG cell generation was decreased but the development of IFN-γ
secreting Th1 cells was not affected (28).
INCREASING TEFF CELL PROLIFERATION
Perhaps the most beneficial approach to boost anti-tumor immu-
nity is to increase activated tumor specific TEFF cell numbers
(Figure 2). The development of IDO inhibitors is one avenue
currently being explored for reactivation of T cells which have
become exhausted or tolerant to tumor antigens. One of the most
widely studied IDO inhibitors is 1-methyl-tryptophan. In com-
bination with other chemotherapeutic agents such as cyclophos-
phamide, it led to the regression of established tumors in a mouse
model of HER-2 breast cancer (95). Another novel IDO inhibitor:
INCB024360 inhibited tumor growth in cell and mouse models
due to increased T cell proliferation and IFN-γ production (96).
Reactivating TEFF cells by increasing tryptophan levels is advanta-
geous over reactivation by increasing glycolysis, due to the similar
glycolytic metabolic pathways used by both T cells and tumor cells
for cell survival and growth (97). Doedens et al. have demon-
strated that genetically activating the HIF-1α pathway in a B16
mouse melanoma tumor cell line can prevent TEFF cell exhaustion
by sustaining the effector functions of T cells despite persistent
antigen exposure (98). As previously discussed, the HIF-1α path-
way can serve as both a positive and negative regulator of TEFF
cells. Further research is required to elucidate the net effect of
using HIF-1α activators to boost TEFF cell-mediated responses
to persistent tumor antigen challenge. Blockade of CTLA-4 by
antibodies prevents the inhibitory signal to the T cell resulting
in an enhanced T cell response against tumor cells and improved
anti-tumor activity (79). Ipilimumab is a fully humanized IgG1
monoclonal antibody against the extracellular domain of CTLA-4
and has been approved for the treatment of metastatic melanoma
(99). Ipilimumab binding to CTLA-4 allows CD28 on the T cell
to bind to the co-stimulatory molecules CD80 and CD86 on
the antigen presenting cell. This is cited as the mechanism of
action of ipilimumab (99). CTLA-4 also inhibits increased glucose
metabolism following T cell activation which is highly relevant
as increased glucose metabolism is vital to sustain the increased
metabolic demands that occur in the transition of a naïve T cell
to a TEFF cell (80, 100). Therefore, it can be concluded from this
evidence that the success of ipilimumab in the treatment of malig-
nant melanoma (101) might be in part due to its negative effects
on glucose metabolism. Some drug therapies currently available
affect T cell metabolism as well as their intended therapeutic tar-
gets. Imatinib is a tyrosine kinase inhibitor originally designed to
target Bcr-Abl in patients with chronic myeloid leukemia (102).
However, it has been shown to have opposing effects on T cell
metabolism. Balachandran et al. found that imatinib can activate
CD8+ T cells and induce TREG cell apoptosis in gastrointestinal
tumors through downregulation of IDO, thus resulting in aug-
mented anti-tumor activity (103). Others found that imatinib
inhibits both normal and leukemic T cell response through the
inhibition of Lck-mediated T cell receptor signaling (104, 105). T
cell receptor signaling is necessary for maximum glucose uptake
following TCR stimulation, through elevated expression and cell
surface trafficking of the glucose transporter Glut1. Without cor-
rect T cell receptor signaling, T cells cannot correctly adjust their
metabolic profile to become TEFF cells and in this manner, imatinib
might be detrimental to T cell mediated anti-tumor immune
responses (58).
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FIGURE 2 | Activation ofT cells results in metabolic reprograming,
which influences their proliferation, differentiation, and effector
functions. Aerobic glycolysis becomes the predominant metabolic
pathway used by CD8+ effector cells, CD4+ Th1, Th2, and Th17 cells, by
contrast TREG and TMEM rely on lipid oxidation. T cells that differentiate into
Th17 cells primarily rely on glycolysis controlled by HIF-1α. TMEM and TREG
rely on lipid oxidation under the control of AMPK. Tumor specific TMEM cell
prevalence can be enhanced through the inhibition of glycolysis following
treatment with the hexokinase-2 inhibitor 2DG. In addition, inhibition of
mTOR by rapamycin and activation of AMPK by the mitochondrial complex
I inhibitor metformin can also led to increased survival of TMEM cells.
Etomoxir, a specific inhibitor of CPT1A results in the reduction of TREG
prevalence and has also shown promising results in delaying tumor
development.
INCREASING TMEM CELL PREVALENCE
Increasing the number of long-lived tumor specific TMEM cells can
lead to sustained anti-tumor activity due to their increased survival
and proliferative capacities. In a study by Sukumar et al., the glu-
cose analog 2-deoxyglucose (2DG), an inhibitor of hexokinase-2
(Hk2), was used to block glycolysis (Figure 2). This resulted in
the increased activity of signaling pathways and transcription fac-
tors that enhance TMEM cell development, such as AMPK which
negatively regulated mTOR and Foxo1, and resulted in enhanced
anti-tumor activity of CD8+ T cells (106). Other methods to
increase the generation of TMEM cells by the modulation of fatty
acid metabolism have also been investigated. Treatment with met-
formin to activate AMPK promoted TMEM cell generation and
was able to significantly improve the efficacy of an experimen-
tal anti-cancer vaccine in vivo (10) (Figure 2). Metformin has
already been shown to inhibit tumor formation due to its direct
action on the tumor, but its use as a potentiator of TMEM cell
activity still requires further investigation (107). Many mecha-
nisms of action have been proposed for the anti-cancer properties
of metformin, including its actions on mTOR (108) and novel
actions such as up-regulation of miR33a resulting in down regu-
lated c-Myc expression (109). Rapamycin, through the inhibition
of mTOR (specifically complex 1) reduces glycolysis and increases
lipid oxidation and can also enhance the formation of TMEM cells
(36) (Figure 2). Other modes of action investigated for rapamycin-
induced development of TMEM cells include the inhibition of the
Th1 promoting transcription factor T-bet and the stabilization of
the expression of the related transcription factor eomesodermin
(110). Treatment of mice with rapamycin following viral infection
not only enhanced frequencies but also accelerated the transition
from TEFF cells to virus specific TMEM cells without inhibiting the
ability of the infected animal to clear the antigen (111). Due to the
multiple actions of mTOR, rapamycin can potentially exert multi-
ple effects on T cell metabolism, particularly its rapid induction of
autophagy, which can be both a pro- and anti-survival process in
T cells (112). Like metformin, rapamycin can directly target and
inhibit tumor cell growth in many ways such as induction of apop-
tosis (113) and inhibiting angiogenesis (114). Unlike metformin
however, rapamycin has immunosuppressive properties and is
used as anti-rejection therapy due to its anti-proliferative actions
(115). Although to date, the anti-cancer effects of rapamycin and
its derivatives are more prominent than the immunosuppressant
effects, further research is warranted to ensure this is also the case
in the long term (116). Another important role for any drugs
developed to enhance the formation of TMEM cells is to enhance
the efficacy of cancer vaccines. The main goal of any vaccination
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is to induce an effective TMEM cell response (117), many of the
experiments targeting TMEM cell generation have a better recall
response and are more protective following re-challenge (111).
TARGETING T CELL METABOLISM TO PREVENT AND TREAT
OBESITY-ASSOCIATED CANCER
Obesity induces a state of tumor-promoting chronic inflamma-
tion, marked by elevated levels of free fatty acids, abnormal
cytokine production, and activation of inflammatory signaling
pathways (118, 119). The expansion of VAT in obesity, results in
increased blood supply, inflammatory immune cell infiltration,
and enhanced pro-inflammatory cytokine release (9, 120–122,
126). Our group have previously shown that activated IFN-γ pro-
ducing CD4+ and CD8+ T cells are significantly enriched in obese
VAT, while others have found that frequencies of TREG cells are
decreased (9, 123, 124). Therefore, obese VAT is characterized by
an increased prevalence of pro-inflammatory T cells and reduced
numbers of anti-inflammatory T cells, which is likely to contribute
to adipose tissue inflammation and the clinical manifestations
of obesity, including cancer. Developing effective immunothera-
pies for obesity-associated malignancies represents a unique chal-
lenge; to attenuate chronic systemic inflammation while simul-
taneously augmenting specific immunity at tumor sites. As pro-
inflammatory Th1 cells appear to play a crucial role in obesity-
associated inflammation, the alteration of the metabolic profile
of T cells in the VAT may present a favorable therapeutic option.
There is currently a paucity of studies investigating the efficacy of
targeting immunometabolism as a mechanism to control tumor-
promoting systemic inflammation associated with obesity. How-
ever, there is some precedence for targeting metabolism to control
systemic inflammation in autoimmune diseases. For instance,
inhibition of both the mTOR and MAPK (ERK) pathways using
rapamycin and the MEK1/2 inhibitor PD325901 was identified as
a means of robustly blocking effector CD4+ T cell proliferation in
a mouse model of arthritis (84). This study found that inhibition
of both pathways was more effective than inhibiting either mTOR
or ERK alone and resulted in greatly decreased disease severity in
a mouse model of arthritis. Since our group has previously identi-
fied TEFF cells as key players in adipose tissue inflammation, ERK
and mTOR inhibitors might elicit a similar anti-inflammatory
effect in obesity (9). Others have found that beauvericin-mediated
inhibition of T cell activation in colitis was achieved by target-
ing P13K and AKT (86). Treatment with beauvericin reduced
pro-inflammatory cytokine production, weight loss, diarrhea,
and mortality in this mouse model of colitis (86). In addition,
pro-inflammatory cytokine production and clinical symptoms in
experimental autoimmune uveitis (EAU) were reduced through
the inhibition of PI3K/AKT by a novel anti-angiogenic peptide
H-RN, thus presenting another potential therapeutic option for
attenuating obesity-associated inflammation (87). The small mol-
ecule inhibitor IPI-145 has also shown promising therapeutic value
in the blockade of PI3K in collagen-induced arthritis, ovalbumin-
induced asthma, and systemic lupus suggesting that this molecule
might be applicable and effective in autoimmune and multiple
inflammatory disorders, including obesity (85). The inhibitor
elicited its effects through blockade of both PI3K-δ and PI3K-γ
and subsequent suppression of both innate and adaptive immune
responses. This resulted in reduced pro-inflammatory cytokine
production and disease severity in all mouse models tested (85).
From these studies, it appears that anti-inflammatory agents tar-
geting PI3K, AKT, and mTOR could be a favorable option in the
treatment of obesity-associated inflammation and cancer. How-
ever, metabolic targets for the treatment of obesity-associated
cancer and disease should first be identified through definitive
studies that will elucidate the metabolic profiles of T cells in VAT
and the corresponding tumor. A therapy targeting specific meta-
bolic pathways of VAT T cells could be used alone as a prophylactic
in obese individuals who are at risk of developing malignancy or in
combination with standard therapies in patients who have already
developed an obesity-associated malignancy. Focused studies are
currently lacking but clearly warranted in this area.
CONCLUSION
It is clear that T cell survival, function, and differentiation are inti-
mately linked to T cell metabolism. The increase in glycolysis and
glutaminolysis facilitate the rapid proliferation of T cells required
during activation to allow fast clearance of pathogens or tumor
cells. TREG and TMEM cells favor FAO, which allows these cells to
survive long term, when glucose and growth factors are limited.
This ensures the control of inappropriate immune responses and
long term immunity. Extensive metabolic reprograming not only
fulfils the extra biosynthetic demands of activated T cells, but it is
also integrated with signaling pathways that determine T cell fate,
thus enhancing our understanding of distinct T cell subset func-
tion and regulation. The different metabolic pathways may also
provide a new opportunity for modulating the immune response
during tumor development and progression. One of the hallmarks
of cancer is evasion of the immune system (125) and in the past few
years our understanding of how this occurs has greatly improved.
One area which holds promise for cancer immunotherapy is the
manipulation of immune responses, such that TEFF and TMEM
cell-mediated responses are enhanced, while those of TREG cells
are decreased, ultimately providing a therapy that might “switch”
back on the immune system to target the tumor cell. Reactivating
exhausted T cells by adjusting their metabolism also holds poten-
tial as a treatment for cancer, however more research needs to be
carried out to fully elucidate the role of cellular metabolism in T
cell exhaustion. Due to the similarities between tumor cells and
activated T cell’s metabolic programing, any therapies designed
to modulate tumor cell metabolism must take into account their
effects on T cell metabolism in the immune response to cancer.
Since the WHO now estimates that obesity is directly attrib-
utable for as many as 41% of malignancies and with the rates
of obesity continuing to increase dramatically, it is clear that
novel therapeutic options are urgently required. Since activated
inflammatory TEFF cells are found to be enriched in the VAT
of cancer patients, it is likely that they play pathological roles
in driving obesity-associated inflammation. Attenuation of this
inflammation might be achieved via metabolic manipulation of
inflammatory TEFF cell differentiation and activation. Suppression
of excessive pro-inflammatory T cell responses through inhibition
of metabolic pathways has already been demonstrated across a
spectrum of chronic inflammatory disorders in mice and could
represent a viable therapeutic target for obesity-associated cancers.
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The possibilities of modulating anti-tumor immune responses
through targeting T cell metabolic pathways hold huge promise
and clearly warrant further investigation.
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